1

# Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment

3

2

4 Yu Jiang,<sup>1,41</sup> Travis J. Meyers,<sup>1,41</sup> Adaeze A. Emeka,<sup>2</sup> Lauren Folgosa Cooley,<sup>2</sup> Phillip R. Cooper,<sup>2</sup> Nicola Lancki,<sup>3</sup> Irene Helenowski,<sup>3</sup> Linda Kachuri,<sup>1</sup> Daniel W. Lin,<sup>4,5</sup> Janet L. 5 Stanford,<sup>6,7</sup> Lisa F. Newcomb,<sup>4,5</sup> Suzanne Kolb,<sup>6,7</sup> Antonio Finelli,<sup>8</sup> Neil E. Fleshner,<sup>8</sup> Maria 6 Komisarenko,<sup>8</sup> James A. Eastham,<sup>9</sup> Behfar Ehdaie,<sup>9</sup> Nicole Benfante,<sup>9</sup> Christopher J. 7 Logothetis,<sup>10</sup> Justin R. Gregg,<sup>10</sup> Cherie A. Perez,<sup>10</sup> Sergio Garza,<sup>10</sup> Jeri Kim,<sup>10</sup> Leonard S. 8 Marks,<sup>11</sup> Merdie Delfin,<sup>11</sup> Danielle Barsa,<sup>11</sup> Danny Vesprini,<sup>12</sup> Laurence H. Klotz,<sup>12</sup> Andrew 9 Loblaw,<sup>12</sup> Alexandre Mamedov,<sup>12</sup> S. Larry Goldenberg,<sup>13</sup> Celestia S. Higano,<sup>13</sup> Maria Spillane,<sup>13</sup> 10 Eugenia Wu,<sup>13</sup> H. Ballentine Carter,<sup>14</sup> Christian P. Pavlovich,<sup>14</sup> Mufaddal Mamawala,<sup>14</sup> Tricia 11 Landis,<sup>14</sup> Peter R. Carroll,<sup>15</sup> June M. Chan,<sup>1,15</sup> Matthew R. Cooperberg,<sup>15,16</sup> Janet E. Cowan,<sup>15</sup> 12 Todd M. Morgan,<sup>17</sup> Javed Siddigui,<sup>18</sup> Rabia Martin,<sup>18</sup> Eric A. Klein,<sup>19</sup> Karen Brittain,<sup>19</sup> Paige 13 Gotwald,<sup>19</sup> Daniel A. Barocas,<sup>20</sup> Jeremiah R. Dallmer,<sup>20,21</sup> Jennifer B. Gordetsky,<sup>20,22</sup> Pam 14 Steele,<sup>20</sup> Shilajit D. Kundu,<sup>2</sup> Jazmine Stockdale,<sup>2</sup> Monique J. Roobol,<sup>23</sup> Lionne D.F. 15 Venderbos,<sup>23</sup> Martin G. Sanda,<sup>24</sup> Rebecca Arnold,<sup>24</sup> Dattatrava Patil,<sup>24</sup> Christopher P. Evans,<sup>25</sup> 16 Marc A. Dall'Era,<sup>25</sup> Anjali Vij,<sup>25</sup> Anthony J. Costello,<sup>26</sup> Ken Chow,<sup>26</sup> Niall M. Corcoran,<sup>26</sup> Soroush 17 Rais-Bahrami.<sup>27,28</sup> Courtney Phares.<sup>27</sup> Douglas S. Scherr.<sup>29</sup> Thomas Flynn.<sup>29</sup> R. Jeffrey 18 Karnes,<sup>30</sup> Michael Koch,<sup>31</sup> Courtney Rose Dhondt,<sup>31</sup> Joel B. Nelson,<sup>32</sup> Dawn McBride,<sup>32</sup> Michael 19 S. Cookson,<sup>33</sup> Kelly L. Stratton,<sup>33</sup> Stephen Farriester,<sup>33</sup> Erin Hemken,<sup>33</sup> Walter M. Stadler,<sup>34</sup> 20 Tuula Pera,<sup>34</sup> Deimante Banionyte,<sup>34</sup> Fernando J. Bianco Jr.,<sup>35</sup> Isabel H. Lopez,<sup>35</sup> Stacy Loeb,<sup>36</sup> 21 Samir S. Taneja,<sup>36</sup> Nataliya Byrne,<sup>36</sup> Christopher L. Amling,<sup>37</sup> Ann Martinez,<sup>37</sup> Luc Boileau,<sup>37</sup> 22 Franklin D. Gaylis,<sup>38</sup> Jacqueline Petkewicz,<sup>39</sup> Nicholas Kirwen,<sup>39</sup> Brian T. Helfand,<sup>39</sup> Jianfeng 23 Xu,<sup>39</sup> Denise M. Scholtens,<sup>3</sup> William J. Catalona,<sup>2, 42</sup> John S. Witte<sup>1,15,16, 40, 42</sup> 24

25

- 27 <sup>1</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA
- 28 94158, USA
- 29 <sup>2</sup>Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
- 30 <sup>3</sup>Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of
- 31 Medicine, Chicago, IL 60611, USA
- 32 <sup>4</sup>Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle,
- 33 WA 98109, USA
- 34 <sup>5</sup>Department of Urology, University of Washington, Seattle 98195, WA, USA
- 35 <sup>6</sup>Fred Hutchinson Cancer Research Center, Cancer Epidemiology Program, Public Health Sciences,
- 36 Seattle, WA 98109, USA
- 37 <sup>7</sup>Department of Epidemiology, University of Washington, School of Public Health, Seattle, WA 98195, USA
- 38 <sup>8</sup>Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network,
- 39 Toronto, Ontario, Canada
- 40 <sup>9</sup>Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 41 <sup>10</sup>Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer
- 42 Center, Houston, TX, USA
- 43 <sup>11</sup>Department of Urology, David Geffen School of Medicine at UCLA, USA
- 44 <sup>12</sup>Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON,
- 45 Canada
- 46 <sup>13</sup>Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
- 47 <sup>14</sup>Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 48 <sup>15</sup>Department of Urology, University of California, San Francisco, San Francisco, CA, USA
- 49 <sup>16</sup>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San
- 50 Francisco, CA, USA
- 51 <sup>17</sup>Department of Urology, University of Michigan, Ann Arbor, MI, USA
- 52 <sup>18</sup>Department of Pathology, University of Michigan, Ann Arbor, MI, USA
- 53 <sup>19</sup>Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic,
- 54 USA

- 55 <sup>20</sup>Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA
- 56 <sup>21</sup>Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 57 <sup>22</sup>Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville,
- 58 TN, USA
- 59 <sup>23</sup>Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Center, Rotterdam, the
- 60 Netherlands
- 61 <sup>24</sup>Department of Urology, Emory University School of Medicine, Atlanta, GA, USA
- 62 <sup>25</sup>Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, CA, USA
- 63 <sup>26</sup>Department of Urology, Royal Melbourne Hospital and University of Melbourne, Australia
- 64 <sup>27</sup>Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA
- 65 <sup>28</sup>Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA
- 66 <sup>29</sup>Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA
- 67 <sup>30</sup>Mayo Clinic Department of Urology, Rochester, MN, USA
- 68 <sup>31</sup>Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA
- 69 <sup>32</sup>Department of Urology, University of Pittsburgh School of Medicine, PA, USA
- <sup>33</sup>Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- 71 <sup>34</sup>University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
- 72 <sup>35</sup>Urological Research Network, Miami Lakes, FL, USA
- 73 <sup>36</sup>Departments of Urology and Population Health, New York University Langone Health and Manhattan
- 74 Veterans Affairs Medical Center, New York, NY, USA
- 75 <sup>37</sup>Department of Urology, Oregon Health and Science University, Portland, OR, USA
- 76 <sup>38</sup>Genesis Healthcare Partners, Department of Urology, University of California, San Diego, CA, USA
- <sup>39</sup>Division of Urology, NorthShore University Health System, Evanston, IL, USA
- <sup>40</sup>Departments of Epidemiology and Population Health, Biomedical Data Science, and Genetics, Stanford
- 79 University, Stanford, CA, USA
- <sup>41</sup>These authors contributed equally to the first authorship.
- 81 <sup>42</sup>These authors contributed equally to the senior authorship.
- 82

- 83 Correspondence to John S. Witte (jswitte@stanford.edu)
- 84
- 85 **Descriptive running head:** Genetics of prostate cancer conversion from active surveillance
- 86 Keywords (MeSH Headings): prostatic neoplasms; prostate; genome-wide association study,
- 87 genetics
- 88 Support: NIH grant P50CA180995; CIDR Contract # HHSN2682017000061

#### 89 Abstract

90 Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for 91 92 prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most 93 heritable cancers, and genetic factors that predispose to aggressive tumors may help 94 distinguish men who are more likely to discontinue AS. To investigate this, we undertook a 95 multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially 96 elected AS and were followed over time for the potential outcome of conversion from AS to 97 active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) 98 associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion (MAST3,  $p = 6.9 \times 10^{-7}$  and GAB2,  $p = 2.0 \times 10^{-6}$ ). 99 100 Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC 101 was positively associated with conversion (e.g., comparing the highest to the two middle deciles 102 gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing 103 values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated 104 with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% 105 CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize 106 the decision of AS—or the intensity of monitoring on AS—versus treatment for the initial 107 management of patients with low-risk PC.

#### 108 Introduction

109 Active surveillance (AS) is now more widely implemented as an initial management strategy for many men with lower-risk prostate cancer (PC [MIM: 176807])<sup>1</sup>. PC that is unlikely to invade 110 111 surrounding tissue or metastasize according to characteristics at diagnosis is considered "low-112 risk" or "favorable-intermediate risk"<sup>2</sup>. Recent work in the United States Veterans Administration (VA) Health Care System<sup>3,4</sup> and in Sweden<sup>5</sup> indicates that a majority of men with low-risk PC 113 114 are being managed with AS. Determining which patients most benefit from early active 115 treatment versus AS, however, and how intensive the surveillance protocol should be, remains 116 a challenge.

117

118 A major drawback of AS for low-risk PC is the possibility of misclassifying patients with life-119 threatening disease. In fact, over a 10-year follow-up period, 20-40% of men initially managed with AS later have more aggressive cancer<sup>6</sup>. While the impact of delayed treatment is unknown, 120 121 up to 50% of men in one AS series of studies experienced biochemical recurrence after active 122 treatment<sup>7</sup>. These uncertainties and challenges in accurately discriminating between indolent 123 and aggressive PC may prompt men to err on the side of early treatment resulting in 124 unnecessary side effects and worse health-related quality of life, or conversely result in delays 125 in therapy for men who are likely to benefit from it. Many men have such low-risk disease that they do not need the biopsies or scans with the frequency with which they have typically been 126 127 performed. Recent work suggests that the likelihood of risk reclassification of an individual patient's disease might be predicted for at least four years of AS<sup>8</sup>. Thus, it may be possible 128 129 reduce the intensity of surveillance for many men with the lowest-risk tumors.

130

A key outstanding question is how to best distinguish among low- and high-risk tumors for AS decisions. Promising recent developments for enhancing clinical risk assessment include multiparametric MRI with targeted prostate biopsy and tissue-based genomic testing<sup>9,10</sup>. Another 134 potentially valuable approach is incorporating germline genetic information for PC via a polygenic risk score<sup>11</sup>. PC is one of the most heritable of common cancers, with germline 135 denetic factors accounting for over 40% of the variability in this disease<sup>12–15</sup>. We and others 136 137 have identified from genome-wide association studies (GWAS) 269 common germline genetic 138 variants associated with PC susceptibility that explain a substantial proportion of disease heritability<sup>16–43</sup>. Combining these PC risk variants together into a genetic risk score (GRS) may 139 140 provide a more discriminatory biomarker not only for PC risk, but also potentially for predicting conversion from AS to treatment<sup>44–47</sup>. Moreover, we recently have discovered genetic variants 141 that explain variability in PSA levels<sup>48</sup>. Since PSA is a critical component to monitoring men 142 143 undergoing AS, incorporating this information may also help to identify ideal AS candidates.

144

To evaluate the potential value of incorporating germline genetic information into the shared decision-making process for AS, we present findings from a large, multi-institutional GWAS of men diagnosed with PC enrolled in an AS program. We report novel variants and genes, and genetic risk scores associated with conversion from AS to treatment.

149

#### 150 Material and Methods

151 Participants

152 The primary study participants came from 28 institutions in the US, Canada, the Netherlands, 153 and Australia. We recently reported on the clinicopathological characteristics of conversion to treatment in this population<sup>49</sup>. The initial study population included 7,279 men diagnosed with 154 155 PC between 1991 and 2018 who elected AS for their initial management. We also included an 156 additional 593 AS patients from the University of Texas MD Anderson Cancer Center as 157 replication samples, described below. Patients' blood or tissue samples were collected to 158 conduct germline genetic analyses. The AS protocols varied among participating institutions, reflecting real-world practice patterns<sup>50–53</sup>, and we did not impose strict inclusion/exclusion 159

criteria based on the AS protocol. Patient demographic and clinical variables were collected and
managed using the Research Electronic Data Capture (REDCap) software<sup>54,55</sup>. Men without
data on the duration of AS (235, 3.2%) and those managed with AS for less than six months
(269, 3.7%) were excluded, leaving 6,775 men for potential inclusion in the GWAS. This study
was approved by the institutional review board at each institution, all participants provided
written informed consent, and all participating institutions signed a material transfer and data
use agreement.

167

# 168 Clinical and Demographic Factors

169 We collected PC characteristics at diagnosis, including the age at diagnosis, Gleason grade 170 group (GG), PSA level, clinical tumor stage (cT), and the number of cancerous biopsy cores at 171 diagnosis. Grade groups correspond to the following Gleason scores (GS): GG1 ~ GS <6; GG2 ~ GS 3+4; GG3 ~ GS 4+3; GG4 ~ GS 8; GS 5 ~ GS 9 or 10<sup>56</sup>. Study participants were classified 172 173 into three risk groups (low-, intermediate-, and high-risk) based on our modification of guidelines 174 from the National Comprehensive Cancer Network (NCCN) and the American Urological 175 Association (AUA). We did not strictly follow these guidelines because we were unable to 176 distinguish between cT2a, cT2b, and cT2c, and we did not have data on PSA density (serum 177 PSA concentration divided by prostate volume). Therefore, *low-risk* patients met the following 178 criteria: Gleason grade group 1 (GG1) (Gleason score 3+3), PSA <10 ng/mL, clinical-stage cT1, 179 and <3 positive biopsy cores. Intermediate-risk patients had any of the following without any 180 high-risk or high-volume criteria: GG2 (Gleason 3+4), PSA 10-20 ng/mL, or stage cT2. High-risk 181 patients had any of the following: ≥ GG3 (≥ Gleason 4+3), PSA ≥20 ng/mL, stage ≥cT3, or ≥4 182 positive biopsy cores of any GG.

183

184 Conversion occurred when a patient received treatment following AS. The reason for
185 withdrawing from AS to begin treatment was reported as due to "upgrading", "upstaging", "PSA

186 progression", "anxiety", and/or "other" reasons. Note that in our survival analysis (below),

187 individuals who converted due to anxiety were censored and do not contribute events in our

analysis. We used the ADMIXTURE software program to infer genetic ancestry from

189 uncorrelated SNPs, according to major reference populations in the 1000 Genomes Project

190 (European, African, East/South Asian combined, and Admixed American)<sup>57</sup>.

191

192 Genotyping and Imputation

193 In total, 6,324 participants were genotyped on the Illumina Infinium Multi-Ethnic Global Array

194 (MEGA), including custom content, at the NIH Center for Inherited Disease Research (CIDR) at

195 Johns Hopkins University. Genotypes were called using GenomeStudio version 2011.1,

Genotyping Module version 1.9.4, and GenTrain Version 1.0. The full array with custom contentconsisted of 1,760,143 SNPs.

198

199 After genotyping, the median SNP call rate was 99.94%, and the error rate estimated from 122 pairs of planned study duplicates was 1.3x10<sup>-6</sup>. Samples and variants were excluded if they had 200 201 a sample or genotyping call rate < 98%. We limited our analyses to variants with a minor allele 202 frequency (MAF) > 1%. Variants were screened for deviations from Hardy-Weinberg equilibrium with a filter threshold of p=6.5x10<sup>-4</sup>. A total of 856,077 genotyped SNPs remained after these 203 204 quality control (QC) steps. Unmeasured genetic variants were imputed using the Trans-Omics 205 for Precision Medicine (TOPMed) Imputation Server, with 97,256 reference samples and 206 308,107,085 SNPs. Variants with imputation guality (INFO) score < 0.3 were excluded, leaving 207 a total of 22,691,641 SNPs successfully imputed. After QC steps, a total of 5,936 samples 208 genotyped at CIDR remained for inclusion in the GWAS.

209

Furthermore, we included in our analysis an additional 593 AS patients from MD Anderson
previously genotyped on the Illumina Infinium OncoArray-500K BeadChip Array. This array was

212 primarily developed to study cancer predisposition and risk. Genotypes were called using 213 GenomeStudio version 2011.1. The full array consisted of 500,000 SNPs. Genotype QC 214 procedures and imputation for the PRACTICAL OncoArray have been described previously<sup>15</sup>. 215 Briefly, imputation was performed without pre-phasing with SHAPEIT2 based on the 1000 216 Genomes Phase 3 release reference panel. In total, 21,299,194 SNPs were successfully 217 imputed, and 10,109,977 variants with MAF ≥ 1% on autosomal chromosomes 1-22 and sex 218 chromosome X.

219

## 220 GWAS of Conversion from AS to Treatment

221 The variants with MAF > 1% on autosomal chromosomes 1-22 and sex chromosome X were 222 tested for their association with time to conversion from AS to treatment among the 5,222 men 223 of European genetic ancestry genotyped by CIDR. Patients who converted due to anxiety were 224 censored because the event of interest was converting due to a change in the cancer clinical 225 characteristics. Per-allele hazard ratios (HRs), 95% confidence intervals (CIs), and 226 corresponding p-values were calculated from Cox proportional hazards models. HRs were 227 adjusted for age at diagnosis and the first 10 genetic principal components to address potential 228 population stratification or cryptic relatedness. Adjusted HRs were calculated using the gwasurvivr package in R<sup>58</sup>. For any variants associated with conversion, we examined the Cox 229 230 models' proportional hazards assumption.

231

Following the GWAS discovery phase, the potential associations were tested for replication in
an independent GWAS among 1,139 men also genotyped by CIDR (but of non-European
ancestry) and the 425 MD Anderson samples of European genetic ancestry (excluding other
ancestries). Again, variants with MAF ≥ 1% on autosomal chromosomes and sex chromosome
X were tested for their association with conversion within major ancestral populations (i.e.,
European, African, Asian, and Admixed American). For the MD Anderson patients, 9,962,324

variants were tested in a Cox proportional hazards model adjusted for age at PC diagnosis andancestry principal components.

240

241	Results from the GWAS were combined with a fixed-effects inverse-variance-weighted meta-
242	analysis using METAL <sup>59</sup> . All statistical tests were two-sided. Marginal P values less than 5x10 <sup>-8</sup>
243	were considered statistically significant. We defined a locus as the 1 megabase (Mb) region
244	surrounding the sentinel variant (500 kilobase pairs flanking each side). To identify
245	independently associated variants, within each 1 Mb region we performed clumping on the
246	association results using PLINK v1.9 using a linkage disequilibrium threshold $r^2 < 0.5$ ).
247	
248	Transcriptome-Wide Association Study of Conversion from AS to Treatment
249	To identify additional genes associated with time to conversion, we conducted a transcriptome-
250	wide association analysis (TWAS), which models genetically imputed transcript levels and has a
251	lower multiple testing burden compared to single-variant analysis. We applied the MetaXcan
252	analytic pipeline to our GWAS summary statistics and associated genetically predicted
253	expression of approximately 22,000 genes across 49 issue reference datasets from GTEx
254	(version 8) <sup>60</sup> . Tissue-specific associations were aggregated using S-MultiXcan to obtain cross-
255	tissue p-values for each gene <sup>60</sup> . Associations were considered statistically significant at the
256	Bonferroni-corrected alpha level of 2.2x10 <sup>-6</sup> (i.e., 0.05/22,535 genes).
257	
258	Genetic Risk Scores
259	Genetic risk scores (GRS) were constructed by summing variant-specific weighted allelic
260	dosages for the samples genotyped by CIDR. The initial GRS included the 269 PC risk variants

reported in the largest trans-ancestry GWAS meta-analysis of PC<sup>43</sup>. Specifically, for patient *i*,

262  $GRS_i = \sum_{m=1}^{M} w_m g_{im}$ , where  $g_{im}$  is the genotype dosage for patient *i*, and variant *m*, and  $w_m$  is

263 the variant weight on the log odds ratio scale from the published literature (i.e., the meta-

264 analysis for the  $GRS_{PC}$ ). M is the total number of variants included in the GRS (M = 269 for the 265 GRS<sub>PC</sub>). A second GRS was developed for the genetic basis of serum PSA levels. This GRS<sub>PSA</sub> 266 included 36 variants and their corresponding weights from a GWAS of PSA levels among cancer-free men.<sup>48</sup> The associations between these GRS and conversion were estimated using 267 268 multivariable Cox proportional hazards models. Minimally adjusted Cox models included age 269 and the first 10 genetic principal components. Fully adjusted Cox models also included Gleason 270 grade group (GG1, GG2, or  $\geq$  GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or 271 cT3/cT4); and number of positive biopsy cores (1-2, 3, or  $\geq$  4). The GRS was modeled as a 272 categorical variable according to deciles of the distribution, and HRs for each decile were 273 estimated with the 40-60th percentile group as the reference.

274

275 Clinical Utility of the GRS

The potential utility of the GRS was evaluated by comparing how the top and bottom deciles of the GRS distribution modified conversion rates within the three PC clinicopathological risk categories (i.e., low-, intermediate-, and high-). For the top and bottom GRS deciles (top 10<sup>th</sup> percentile and bottom 10<sup>th</sup> percentile, respectively) we plotted Kaplan–Meier curves of conversion within each PC clinicopathological risk category and tested the difference between each pair of curves with the log-rank test.

282

To evaluate the overall discriminative capacity of the GRS (i.e., not just the decile tails), we calculated the area under the ROC Curve (AUC) in the discovery sample using regression models of time to conversion. We used Chambless and Diao's estimator of cumulative AUC for right-censored time-to-event data, which is a summary measure given by the integral of AUC on [0, max(times)] weighted by the estimated probability density of the time-to-event outcome<sup>61</sup>. A baseline AUC was calculated for the model that included age and the first 10 principal components. This model was then expanded to further include PC clinical characteristics listed above for the multivariable Cox model, followed by GRS<sub>PC</sub> and GRS<sub>PSA</sub> (individually and
together).

292

293 Results

294 Study Population

295 Details of the discovery and replication samples that met inclusion criteria are presented in Table S1. Clinically, most men had low-risk PC (3,639, 70%) and/or features of low-risk, low-296 297 volume disease: GG1 (4,819, 92%), 1-2 positive biopsy cores (4,113, 79%), and a median PSA 298 at diagnosis of 5 ng/mL. Using genetic information to infer ancestry, 88% were classified as 299 European ancestry. The demographic and clinicopathological characteristics of the replication 300 samples had a similar pattern as the discovery samples, except that the proportion of high-risk 301 PC was higher for men of Asian genetic ancestry (n = 43; 18%) than of European ancestry (n= 302 599; 11%); **Table S1**). Baseline characteristics were missing for the following proportion of 303 study participants: age at diagnosis (<0.1%), GG group (<0.1%), PSA concentration (3.3%), 304 clinical tumor stage (6.9%), number of positive biopsy cores (2.5%), and risk-group classification 305 (<0.1%).

306

307 Genome-Wide Association Study of Conversion from AS to Treatment

308 Our approach to the GWAS discovery, replication, and meta-analysis is outlined in **Figure 1**. 309 The median follow-up time for patients in this multicenter study was 6.7 years. Of the 2,260 310 patients who converted from AS to treatment, 126 (5.6%) converted due to anxiety and were 311 censored in our time-to-event analyses. Our primary discovery GWAS yielded 14 independent lead SNPs (i.e., p-value < 5 x  $10^{-8}$  at each locus of size 1Mb) (Figure 2a). We replicated 1 of the 312 313 signals at a p-value level less than 0.05/14 ( $\approx$  0.0036) in the replication meta-analysis. In the 314 combined meta-analysis of discovery and replication GWAS, we detected four additional SNPs 315 independently associated with conversion to treatment (Figure 2b). Q-Q plots for the discovery

GWAS and the combined meta-analysis did not suggest inflation of test statistics due to
systematic bias such as population substructure (genomic inflation factor =1 and 1.02,
respectively; Figure S1).

319

Of the 18 SNPs, four were common (MAF > 0.01) and the remainder were low frequency (MAF = 0.01) (**Table 1**). Three were located within 1 Mb of previous PC GWAS-identified variants, although they were not in linkage disequilibrium with these variants ( $r^2 < 0.3$ ). These were: intronic SNP rs4721243 of *MAD1L1* (MIM: 602686) on chromosome 7 (CIDR European GWAS  $HR = 5.65, P = 7 \times 10^{-10}$ ); rs1404610 near *GL12* (MIM: 165230; combined meta-analysis HR = $3.74, P = 5.4 \times 10^{-10}$ ) on chromosome 2; and rs74874116 near *GATA5* (MIM: 611496; CIDR

326 European  $HR = 2.67, P = 1.47 \times 10^{-9}$ ) on chromosome 20.

327

328 Transcriptome-Wide Association Study of Conversion from AS to Treatment

329 In the multi-tissue TWAS analysis using S-MultiXcan, the imputed expression levels of two

330 genes were associated with conversion after Bonferroni correction for multiple testing: MAST3

331 (MIM: 612258; P-value= $6.9 \times 10^{-7}$ ) and GAB2 (MIM: 606203; P-value= $2.0 \times 10^{-6}$ ). Imputed

332 expression levels of two other genes suggested association with conversion: ARRDC2 (P-

value= $2.7 \times 10^{-5}$ ) and *CELSR1* (MIM: 604523; P-value= $9.5 \times 10^{-5}$ ). When looking only at

334 prostate tissue, we observed modest associations for MAST3 (P-value=0.08) and GAB2 (P-

value= $4.1 \times 10^{-4}$ ), as well as a suggestive association between imputed expression of the gene

336 *ZNF644* (MIM: 614159) and conversion (P-value= $9.9 \times 10^{-5}$ ).

337

338 Genetic Risk Scores and Conversion from AS to Treatment

339 Increasing GRS for PC susceptibility (GRS<sub>PC</sub>) was positively associated with conversion from

AS to treatment, even after adjusting for clinical covariates (Figure 3a; Table S2). The fully

adjusted HR for conversion for men in the top decile of the  $GRS_{PC}$  compared to the middle two deciles was 1.13 (95% CI, 0.94-1.36; **Figure 3a; Table S2**). Men in the bottom 10<sup>th</sup> percentile of the  $GRS_{PC}$  distribution had a significantly lower conversion rate than the middle two deciles of the  $GRS_{PC}$  (HR=0.69; 95% CI, 0.56-0.86; **Figure 3a; Table S2**).

345

From the 36-variant GRS for PSA concentration (GRS<sub>PSA</sub>), we observed the opposite pattern: increasing GRS<sub>PSA</sub> was inversely associated with conversion (**Figure 3b**; **Table S3**). Compared to the 40-60<sup>th</sup> percentiles, men in the bottom  $10^{th}$  percentile of the PSA GRS distribution experienced a shorter time to conversion (fully adjusted HR=1.25; 95% CI, 1.04-1.50; **Figure 3b**; **Table S3**).

351

352 Potential Clinical Utility of the GRS

The time to conversion in the low- and intermediate-risk groups varied depending on whether men were in the top or bottom deciles of the  $GRS_{PC}$  and  $GRS_{PSA}$  distributions (**Figure 4**). For GRS<sub>PC</sub>, the Kaplan-Meier curves contrasting the top *versus* bottom deciles were significantly different for the low- and intermediate-risk groups (p=3x10<sup>-5</sup> and p=0.016, respectively). Similarly, the top and bottom deciles of the GRS<sub>PSA</sub> differed for the intermediate-risk groups

358 (p=0.003). There was no clear difference between the deciles of GRS<sub>PC</sub> or GRS<sub>PSA</sub> in patients
 359 with high-risk disease.

360

A baseline model including age at diagnosis and principal components achieved an AUC = 0.55 for time to conversion. This was substantially improved by incorporating the clinical characteristics into the model: AUC = 0.653 (**Table S4**). Adding the GRS<sub>PC</sub> to this model resulted in modest improvement (AUC=0.659). Augmenting this model with GRS<sub>PSA</sub> produced minimal improvement (AUC = 0.661).

366

#### 367 Discussion

In this GWAS of PC patients managed with AS, we detected 18 novel SNPs and two candidate genes associated with conversion. We further found that GRS for PC susceptibility in addition to PSA level were associated with conversion, providing information beyond conventional clinical and pathologic measures of the disease. These findings provide preliminary support for using germline genetic information to inform the initial management of men with newly diagnosed, clinically localized PC.

374

375 Of the 18 SNPs associated with conversion, 15 were not previously associated with PC risk. 376 These include a low-frequency (MAF = 0.01) intronic variant, rs4721243 at MAD1L1, at a previously identified PC locus<sup>43</sup>. The SNP was uncorrelated with the previously reported 377 genome-wide significant PC SNP at the locus (rs4513875,  $r^2 = 0.012$  in the 1000 Genomes 378 global reference data). One detected SNP (rs74874116) was 32kb away from a PC-associated 379 indel (rs139135938), with little correlation ( $r^2 = 0.015$  in 1000 Genomes). The neighboring 380 381 gene, GATA5, encodes a transcription factor that contains two GATA-type zinc fingers and is required during cardiovascular development<sup>62</sup>. This gene contains two variants previously 382 associated with benign prostatic hyperplasia (MIM: 600082) and associated lower urinary tract 383 symptoms<sup>63</sup> (MIM: 618612). Another SNP in a PC risk locus was rs1404610, nearby GLI2, a 384 385 transcription factor that one study found regulates the growth and tumorigenicity of prostate cells<sup>64</sup>. 386

387

Many of the novel SNPs we found to be associated with conversion are intronic, including SNPs in genes involved in cellular signaling, growth, and differentiation. *PRDM16* (MIM: 605557), where rs6658664 is located, is associated with evasion of apoptosis by prostatic cancer cells<sup>65</sup>. Intronic SNP rs115861550 in *VAV2* (MIM: 600428) is upregulated in human PC tumors and is a prognostic indicator for poor outcome<sup>66</sup>. Another intronic SNP, *EBF3* (MIM: 607407), has been 393 shown to regulate the expression of genes involved in cell growth, proliferation, and apoptosis<sup>67</sup>. 394 RECQL5 (MIM: 603781), where SNP rs820198 is located, regulates DNA repair intermediate structures, and studies have observed elevated RECQL5 expression in other cancers such as 395 396 breast (MIM: 114480) and bladder (MIM: 109800)<sup>68-70</sup>. SNP rs820198 is annotated to an active 397 CTCF (CCCTC-binding factor) binding site, and CTCF expression in linked to poor outcome in prostate cancer<sup>71</sup>. Although intergenic, SNP rs77112978 is near NEDD4L (MIM: 606384), 398 399 whose expression is decreased in PC<sup>72</sup>. Intergenic SNP rs55850837-A, associated with conversion in our study, was associated with reduced body mass index<sup>73</sup> and body fat 400 percentage<sup>74</sup> in the phenome-wide association data curated by the IEU OpenGWAS Project<sup>75</sup>. 401 402 SNP rs12452625, a UTR'3 variant of RFNG (MIM: 602578) gene, is correlated with variants 403 associated with multiple traits, including heel bone mineral density, lung function, and waist-hip ratio<sup>76,77</sup>. This SNP is also predicted to be a functional target of microRNA hsa-miR-629-3p, 404 405 which may serve as a biomarker for lung metastases of triple-negative breast cancer<sup>78</sup>.

406

407 Our TWAS suggests a possible role for *MAST3* and *GAB2* in conversion. A study described 408 *MAST3* as an inflammatory bowel disease (IBD) susceptibility gene that regulates NF- $\kappa$ B 409 activity through TLR4<sup>79</sup>. Two recent studies have described increased risk for PC in men with 410 IBD (MIM: 601458)<sup>80,81</sup>. Regarding *GAB2*, the knockdown of this gene in PC cells altered the 411 expression of over 1,200 genes and inhibited p53 signaling<sup>82</sup>.

412

We found that the PC GRS based on 269 known risk variants was positively associated with conversion. Moreover, a PSA GRS based on 36 known genetic variants for PSA levels exhibited a weak inverse association with conversion. We expected these GRS to have opposite directions of effect on conversion, given that the PSA GRS may reflect the potential ascertainment of higher-risk PC in men with lower genetically predicted PSA levels. While the 418 overall GRS only contributed modest model discrimination beyond established risk factors for 419 conversion, the associations observed in the tails (i.e., deciles) of the GRS distribution were 420 most pronounced among men in low and intermediate clinicopathological categories. This 421 finding suggests that men with lower-risk disease, but high PC GRS (or low PSA GRS) may be 422 more likely candidates for early treatment or possibly a higher intensity of surveillance. A recent 423 study of European ancestry men with low-risk PC managed on AS reported associations 424 between higher PC GRS with more positive cores and with bilateral tumor location at diagnostic and surveillance biopsy<sup>83</sup>; note that  $\sim$ 50% of the men in this previous study are also included 425 here, comprising ~10% of our study population. 426

427

428 Strengths of this study include leveraging a large, multi-institutional collaborative study of AS to 429 model the effects of genetic risk variants independent of clinical risk parameters. Sixty-three 430 percent of the replication sample (n = 714) were men of non-European genetic ancestry, 431 allowing us to test the generalizability of the SNPs discovered in the European sample. Our 432 GRS included the most recently available GWAS weights from PC and PSA. Limitations of our 433 study included the lack of confirmatory or surveillance biopsies to reduce misclassification of 434 clinical parameters at diagnosis and follow-up. In addition, conversion could conflate disease 435 progression with patient anxiety and/or physician preference for AS management. However, 436 discontinuing AS due to anxiety was relatively uncommon in this study (about 6% of events). 437 and these cases were censored in the GWAS analysis. Furthermore, given the relatively short 438 follow-up for more robust PC outcomes, the sample sizes for PSA failure after treatment 439 (n=124), metastases (n=29), or PC-specific death (n=11) are too small for a GWAS analysis. 440

In summary, we have undertaken the first GWAS of conversion among men diagnosed
with PC. This multi-institutional study detected a genetic basis of conversion, suggesting

that genetic factors may provide valuable information to stratify men with PC by their
risk of discontinuing AS. Important future work will expand this study to more men
placed on AS, increasing our ability to detect genetic variants associated with
conversion. This may in turn help address concerns that biopsy sampling may
underestimate a tumor's aggressiveness and provide a more personalized approach to
decisions surrounding AS.

449	Supplemental Data
450	Supplemental data include one figure and four tables.
451	
452	Disclosures of Interests
453	The authors declare no competing interests.
454	
455	Declarations
456	This study was approved by the Robert H. Lurie Comprehensive Cancer Center of Northwestern
457	University Scientific Review (IRB) Committees. The approval number is STU00077147, which
458	was most recently given annual approval on 7/8/2021.
459	
460	Acknowledgements
461	Funding/Support: P50CA180995 (William J. Catalona) 08/01/15 – 07/31/20 NIH/NCI SPORE
462	in Prostate Cancer PI on the SPORE grant, Center for Inherited Disease Research (CIDR)
463	award from the NCI for patient sample genotyping (X01HG009642), Urological Research
464	Foundation (William J. Catalona), NorthShore University Health System, Evanston, IL, USA
465	(Brian T. Helfand). Additional support was provided by award numbers R01CA158627 and
466	R01CA195505 (Leonard S. Marks), P50 CA186786 (Todd M. Morgan), UL1 TR000445 from
467	NCATS/NIH for Vanderbilt REDCap (Daniel A. Barocas), P50 CA097186 and K05 CA175147
468	(Janet L. Stanford), and U01 CA113913 (Martin G. Sanda) from the National Institute of Health,
469	and W81XWH-13-2-0074 (Peter R. Carroll) from the Department of Defense.
470	
471	Web Resources
472	METAL (https://genome.sph.umich.edu/wiki/METAL_Documentation)
473	PLINK v1.9 (https://www.cog-genomics.org/plink/)

474 MetaXcan, S-MetaXcan (<u>https://github.com/hakyimlab/MetaXcan</u>)

- 475 IEU OpenGWAS Project (<u>https://gwas.mrcieu.ac.uk/</u>)
- 476 Online Mendelian Inheritance in Man (<u>http://www.omim.org</u>)
- 477
- 478 Data Availability
- 479 The MEGA data analyzed in this publication have been deposited in dbGap and are accessible
- 480 through dbGap Study Accession number phs002056.v1.p1.

#### 481 **References**

- 482 1. Washington, S.L., Jeong, C.W., Lonergan, P.E., Herlemann, A., Gomez, S.L., Carroll, P.R.,
- 483 and Cooperberg, M.R. (2020). Regional Variation in Active Surveillance for Low-Risk Prostate
- 484 Cancer in the US. JAMA Netw Open 3, e2031349.
- 485 2. Mohler, J.L., Antonarakis, E.S., Armstrong, A.J., D'Amico, A.V., Davis, B.J., Dorff, T.,
- 486 Eastham, J.A., Enke, C.A., Farrington, T.A., Higano, C.S., et al. (2019). Prostate Cancer,
- Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw *17*,
  479–505.
- 489 3. Loeb, S., Byrne, N., Makarov, D.V., Lepor, H., and Walter, D. (2018). Use of Conservative
  490 Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care
- 491 System From 2005-2015. JAMA *319*, 2231–2233.
- 492 4. Parikh, R.B., Robinson, K.W., Chhatre, S., Medvedeva, E., Cashy, J.P., Veera, S., Bauml,
- 493 J.M., Fojo, T., Navathe, A.S., Malkowicz, S.B., et al. (2020). Comparison by Race of
- 494 Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans
- 495 From 2004 to 2018. JAMA Netw Open 3, e2018318.
- 496 5. Loeb, S., Folkvaljon, Y., Curnyn, C., Robinson, D., Bratt, O., and Stattin, P. (2017). Uptake of
- 497 Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. JAMA Oncol *3*, 1393–1398.
- 498 6. Stolzenbach, L.F., Rosiello, G., Pecoraro, A., Palumbo, C., Luzzago, S., Deuker, M., Tian, Z.,
- 499 Knipper, A.-S., Pompe, R., Zorn, K.C., et al. (2020). Prostate Cancer Grade and Stage
- 500 Misclassification in Active Surveillance Candidates: Black Versus White Patients. Journal of the
- 501 National Comprehensive Cancer Network *18*, 1492–1499.

- 502 7. Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T.,
- 503 Mamedov, A., and Loblaw, A. (2015). Long-term follow-up of a large active surveillance cohort 504 of patients with prostate cancer. J Clin Oncol *33*, 272–277.
- 505 8. Cooperberg, M.R., Brooks, J.D., Faino, A.V., Newcomb, L.F., Kearns, J.T., Carroll, P.R.,
- 506 Dash, A., Etzioni, R., Fabrizio, M.D., Gleave, M.E., et al. (2018). Refined Analysis of Prostate-
- specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol 74,
  211–217.
- 509 9. Williams, C., Khondakar, N.R., Daneshvar, M.A., O'Connor, L.P., Gomella, P.T., Mehralivand,
- 510 S., Yerram, N.K., Egan, J., Gurram, S., Rompré-Brodeur, A., et al. (2021). The Risk of Prostate
- 511 Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by
- 512 Combined MRI-Fusion and Systematic Biopsy. J Urol 101097JU000000000001941.
- 513 10. Eggener, S.E., Rumble, R.B., Armstrong, A.J., Morgan, T.M., Crispino, T., Cornford, P., van
- der Kwast, T., Grignon, D.J., Rai, A.J., Agarwal, N., et al. (2020). Molecular Biomarkers in
- 515 Localized Prostate Cancer: ASCO Guideline. J Clin Oncol 38, 1474–1494.
- 516 11. Black, M.H., Li, S., LaDuca, H., Lo, M., Chen, J., Hoiness, R., Gutierrez, S., Tippin-Davis,
- 517 B., Lu, H., Gielzak, M., et al. (2020). Validation of a prostate cancer polygenic risk score.
- 518 Prostate *80*, 1314–1321.
- 12. Langeberg, W.J., Isaacs, W.B., and Stanford, J.L. (2007). Genetic etiology of hereditary
  prostate cancer. Front Biosci *12*, 4101–4110.
- 521 13. Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M.,
- 522 Pukkala, E., Skytthe, A., and Hemminki, K. (2000). Environmental and heritable factors in the
- 523 causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J
- 524 Med 343, 78–85.

525 14. Narod, S. (1999). Genetic epidemiology of prostate cancer. Biochim Biophys Acta *1423*, F1526 13.

527 15. Schumacher, F.R., Al Olama, A.A., Berndt, S.I., Benlloch, S., Ahmed, M., Saunders, E.J.,
528 Dadaev, T., Leongamornlert, D., Anokian, E., Cieza-Borrella, C., et al. (2018). Association
529 analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat
530 Genet *50*, 928–936.

531 16. Ahn, J., Kibel, A.S., Park, J.Y., Rebbeck, T.R., Rennert, H., Stanford, J.L., Ostrander, E.A.,

532 Chanock, S., Wang, M.-H., Mittal, R.D., et al. (2011). Prostate cancer predisposition loci and

risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res 17, 1075–1081.

17. Amin Al Olama, A., Kote-Jarai, Z., Schumacher, F.R., Wiklund, F., Berndt, S.I., Benlloch, S.,
Giles, G.G., Severi, G., Neal, D.E., Hamdy, F.C., et al. (2013). A meta-analysis of genome-wide
association studies to identify prostate cancer susceptibility loci associated with aggressive and
non-aggressive disease. Hum Mol Genet *22*, 408–415.

538 18. Bao, B.-Y., Pao, J.-B., Huang, C.-N., Pu, Y.-S., Chang, T.-Y., Lan, Y.-H., Lu, T.-L., Lee, H.-

539 Z., Chen, L.-M., Ting, W.-C., et al. (2012). Significant associations of prostate cancer

susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J
Cancer *130*, 876–884.

542 19. Bensen, J.T., Xu, Z., Smith, G.J., Mohler, J.L., Fontham, E.T.H., and Taylor, J.A. (2013).

543 Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS

and candidate SNPs in African-Americans and European-Americans. Prostate 73, 11–22.

20. Chen, M., Huang, Y.-C., Yang, S., Hsu, J.-M., Chang, Y.-H., Huang, W.J.-S., and Chen, Y.-

546 M.A. (2010). Common variants at 8q24 are associated with prostate cancer risk in Taiwanese

547 men. Prostate 70, 502–507.

- 548 21. Eeles, R.A., Kote-Jarai, Z., Giles, G.G., Olama, A.A.A., Guy, M., Jugurnauth, S.K.,
- 549 Mulholland, S., Leongamornlert, D.A., Edwards, S.M., Morrison, J., et al. (2008). Multiple newly 550 identified loci associated with prostate cancer susceptibility. Nat Genet *40*, 316–321.
- 551 22. Eeles, R.A., Olama, A.A.A., Benlloch, S., Saunders, E.J., Leongamornlert, D.A.,
- 552 Tymrakiewicz, M., Ghoussaini, M., Luccarini, C., Dennis, J., Jugurnauth-Little, S., et al. (2013).
- Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping
  array. Nat Genet *45*, 385–391, 391e1-2.
- 555 23. FitzGerald, L.M., Kwon, E.M., Conomos, M.P., Kolb, S., Holt, S.K., Levine, D., Feng, Z.,

Ostrander, E.A., and Stanford, J.L. (2011). Genome-wide association study identifies a genetic
variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers
Prev *20*, 1196–1203.

559 24. Gudmundsson, J., Sulem, P., Rafnar, T., Bergthorsson, J.T., Manolescu, A., Gudbjartsson,
560 D., Agnarsson, B.A., Sigurdsson, A., Benediktsdottir, K.R., Blondal, T., et al. (2008). Common
561 sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet *40*,
562 281–283.

- 563 25. Gudmundsson, J., Besenbacher, S., Sulem, P., Gudbjartsson, D.F., Olafsson, I.,
- Arinbjarnarson, S., Agnarsson, B.A., Benediktsdottir, K.R., Isaksson, H.J., Kostic, J.P., et al.
- 565 (2010). Genetic correction of PSA values using sequence variants associated with PSA levels.
- 566 Sci Transl Med 2, 62ra92.

26. Helfand, B.T., Loeb, S., Cashy, J., Meeks, J.J., Thaxton, C.S., Han, M., and Catalona, W.J.
(2008). Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer
susceptibility alleles. J Urol *179*, 2197–2201; discussion 2202.

570 27. Helfand, B.T., Kan, D., Modi, P., and Catalona, W.J. (2011). Prostate cancer risk alleles
571 significantly improve disease detection and are associated with aggressive features in patients
572 with a "normal" prostate specific antigen and digital rectal examination. Prostate *71*, 394–402.

28. Lange, E.M., Johnson, A.M., Wang, Y., Zuhlke, K.A., Lu, Y., Ribado, J.V., Keele, G.R., Li, J.,
Duan, Q., Li, G., et al. (2014). Genome-wide association scan for variants associated with earlyonset prostate cancer. PLoS One *9*, e93436.

29. Lange, E.M., Salinas, C.A., Zuhlke, K.A., Ray, A.M., Wang, Y., Lu, Y., Ho, L.A., Luo, J., and
Cooney, K.A. (2012). Early onset prostate cancer has a significant genetic component. Prostate
72, 147–156.

30. Lin, D.W., FitzGerald, L.M., Fu, R., Kwon, E.M., Zheng, S.L., Kolb, S., Wiklund, F., Stattin,
P., Isaacs, W.B., Xu, J., et al. (2011). Genetic variants in the LEPR, CRY1, RNASEL, IL4, and
ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol
Biomarkers Prev 20, 1928–1936.

31. Loeb, S., Carter, H.B., Walsh, P.C., Isaacs, W.B., Kettermann, A., Tanaka, T., Ferrucci, L.,
and Metter, E.J. (2009). Single nucleotide polymorphisms and the likelihood of prostate cancer
at a given prostate specific antigen level. J Urol *182*, 101–104; discussion 105.

586 32. Pal, P., Xi, H., Guha, S., Sun, G., Helfand, B.T., Meeks, J.J., Suarez, B.K., Catalona, W.J.,

and Deka, R. (2009). Common variants in 8q24 are associated with risk for prostate cancer and

tumor aggressiveness in men of European ancestry. Prostate 69, 1548–1556.

589 33. Pomerantz, M.M., Werner, L., Xie, W., Regan, M.M., Lee, G.-S.M., Sun, T., Evan, C.,

590 Petrozziello, G., Nakabayashi, M., Oh, W.K., et al. (2011). Association of prostate cancer risk

591 Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res

592 (Phila) *4*, 719–728.

- 34. Sun, J., Lange, E.M., Isaacs, S.D., Liu, W., Wiley, K.E., Lange, L., Gronberg, H., Duggan,
  D., Carpten, J.D., Walsh, P.C., et al. (2008). Chromosome 8q24 risk variants in hereditary and
  non-hereditary prostate cancer patients. Prostate 68, 489–497.
- 596 35. Xu, J., Zheng, S.L., Isaacs, S.D., Wiley, K.E., Wiklund, F., Sun, J., Kader, A.K., Li, G.,
- 597 Purcell, L.D., Kim, S.-T., et al. (2010). Inherited genetic variant predisposes to aggressive but
- not indolent prostate cancer. Proc Natl Acad Sci U S A *107*, 2136–2140.
- 36. Goh, C.L., and Eeles, R.A. (2014). Germline genetic variants associated with prostate
  cancer and potential relevance to clinical practice. Recent Results Cancer Res 202, 9–26.
- 37. Ishak, M.B., and Giri, V.N. (2011). A systematic review of replication studies of prostate
- 602 cancer susceptibility genetic variants in high-risk men originally identified from genome-wide
- association studies. Cancer Epidemiol Biomarkers Prev *20*, 1599–1610.
- 604 38. Kim, S.-T., Cheng, Y., Hsu, F.-C., Jin, T., Kader, A.K., Zheng, S.L., Isaacs, W.B., Xu, J., and
- Sun, J. (2010). Prostate cancer risk-associated variants reported from genome-wide association
- studies: meta-analysis and their contribution to genetic Variation. Prostate *70*, 1729–1738.
- 39. Lindström, S., Zheng, S.L., Wiklund, F., Jonsson, B.-A., Adami, H.-O., Bälter, K.A., Brookes,
- A.J., Sun, J., Chang, B.-L., Liu, W., et al. (2006). Systematic replication study of reported
- genetic associations in prostate cancer: Strong support for genetic variation in the androgen
  pathway. Prostate *66*, 1729–1743.
- 40. Pomerantz, M.M., and Freedman, M.L. (2010). Genetics of prostate cancer risk. Mt Sinai J
  Med 77, 643–654.

41. Na, R., Liu, F., Zhang, P., Ye, D., Xu, C., Shao, Q., Qi, J., Wang, X., Chen, Z., Wang, M., et
al. (2013). Evaluation of reported prostate cancer risk-associated SNPs from genome-wide
association studies of various racial populations in Chinese men. Prostate *73*, 1623–1635.

42. Bensen, J.T., Xu, Z., McKeigue, P.M., Smith, G.J., Fontham, E.T.H., Mohler, J.L., and

Taylor, J.A. (2014). Admixture mapping of prostate cancer in African Americans participating in

the North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate 74, 1–9.

43. Conti, D.V., Darst, B.F., Moss, L.C., Saunders, E.J., Sheng, X., Chou, A., Schumacher,

620 F.R., Olama, A.A.A., Benlloch, S., Dadaev, T., et al. (2021). Trans-ancestry genome-wide

621 association meta-analysis of prostate cancer identifies new susceptibility loci and informs

622 genetic risk prediction. Nat Genet 53, 65–75.

44. Chen, H., Liu, X., Brendler, C.B., Ankerst, D.P., Leach, R.J., Goodman, P.J., Lucia, M.S.,

Tangen, C.M., Wang, L., Hsu, F.-C., et al. (2016). Adding genetic risk score to family history

identifies twice as many high-risk men for prostate cancer: Results from the prostate cancerprevention trial. Prostate *76*, 1120–1129.

45. Helfand, B.T., Kearns, J., Conran, C., and Xu, J. (2016). Clinical validity and utility of genetic
risk scores in prostate cancer. Asian J Androl *18*, 509–514.

46. Huynh-Le, M.-P., Karunamuni, R., Fan, C.C., Thompson, W.K., Muir, K., Lophatananon, A.,
Tye, K., Wolk, A., Håkansson, N., Mills, I.G., et al. (2021). Common genetic and clinical risk
factors: association with fatal prostate cancer in the Cohort of Swedish Men. Prostate Cancer
Prostatic Dis.

47. Helfand, B.T., and Xu, J. (2021). Germline Testing for Prostate Cancer Prognosis:

634 Implications for Active Surveillance. Urol Clin North Am 48, 401–409.

- 48. Hoffmann, T.J., Passarelli, M.N., Graff, R.E., Emami, N.C., Sakoda, L.C., Jorgenson, E.,
- Habel, L.A., Shan, J., Ranatunga, D.K., Quesenberry, C.P., et al. (2017). Genome-wide
- 637 association study of prostate-specific antigen levels identifies novel loci independent of prostate
- 638 cancer. Nat Commun *8*, 14248.
- 49. Cooley, L.F., Emeka, A.A., Meyers, T.J., Helfand, B.T., Scholtens, D.M., Witte, J.S., and
- 640 Catalona, W.J. Factors Associated with Time to Conversion from Active Surveillance to
- Treatment for Prostate Cancer in a Multi-institutional Cohort. Journal of Urology *Manuscript accepted for publication*,.
- 50. Van Hemelrijck, M., Ji, X., Helleman, J., Roobol, M.J., van der Linden, W., Nieboer, D.,
- Bangma, C.H., Frydenberg, M., Rannikko, A., Lee, L.S., et al. (2019). Reasons for Discontinuing
  Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3
  Consortium. Eur Urol *75*, 523–531.
- 647 51. Gregg, J.R., Davis, J.W., Reichard, C., Wang, X., Achim, M., Chapin, B.F., Pisters, L.,
  648 Pettaway, C., Ward, J.F., Choi, S., et al. (2020). Determining Clinically Based Factors
  649 Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active
  - 650 Surveillance Cohort. Urology *138*, 91–97.
- 52. Welty, C.J., Cowan, J.E., Nguyen, H., Shinohara, K., Perez, N., Greene, K.L., Chan, J.M.,
- Meng, M.V., Simko, J.P., Cooperberg, M.R., et al. (2015). Extended followup and risk factors for
- disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol193, 807–811.
- 53. Hamdy, F.C., Donovan, J.L., Lane, J.A., Mason, M., Metcalfe, C., Holding, P., Davis, M.,
- 656 Peters, T.J., Turner, E.L., Martin, R.M., et al. (2016). 10-Year Outcomes after Monitoring,

- Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine 375,
  1415–1424.
- 54. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009).
- 660 Research electronic data capture (REDCap)--a metadata-driven methodology and workflow
- process for providing translational research informatics support. J Biomed Inform 42, 377–381.
- 55. Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L.,
- 663 Delacqua, G., Delacqua, F., Kirby, J., et al. (2019). The REDCap consortium: Building an
- 664 international community of software platform partners. J Biomed Inform 95, 103208.
- 56. Gordetsky, J., and Epstein, J. (2016). Grading of prostatic adenocarcinoma: current state
  and prognostic implications. Diagn Pathol *11*, 25.
- 57. Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of
  ancestry in unrelated individuals. Genome Res *19*, 1655–1664.
- 58. Rizvi, A.A., Karaesmen, E., Morgan, M., Preus, L., Wang, J., Sovic, M., Hahn, T., and
- 670 Sucheston-Campbell, L.E. (2019). gwasurvivr: an R package for genome-wide survival analysis.
- 671 Bioinformatics 35, 1968–1970.
- 59. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of
  genomewide association scans. Bioinformatics *26*, 2190–2191.
- 674 60. Barbeira, A.N., Pividori, M., Zheng, J., Wheeler, H.E., Nicolae, D.L., and Im, H.K. (2019).
- 675 Integrating predicted transcriptome from multiple tissues improves association detection. PLOS
  676 Genetics *15*, e1007889.
- 677 61. Chambless, L.E., and Diao, G. (2006). Estimation of time-dependent area under the ROC
  678 curve for long-term risk prediction. Stat Med *25*, 3474–3486.

- 679 62. Reiter, J.F., Alexander, J., Rodaway, A., Yelon, D., Patient, R., Holder, N., and Stainier,
- D.Y.R. (1999). Gata5 is required for the development of the heart and endoderm in zebrafish.
  Genes Dev *13*, 2983–2995.
- 682 63. Gudmundsson, J., Sigurdsson, J.K., Stefansdottir, L., Agnarsson, B.A., Isaksson, H.J.,
- 583 Stefansson, O.A., Gudjonsson, S.A., Gudbjartsson, D.F., Masson, G., Frigge, M.L., et al.
- 684 (2018). Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation
- with serum levels of PSA. Nat Commun 9, 4568.
- 686 64. Thiyagarajan, S., Bhatia, N., Reagan-Shaw, S., Cozma, D., Thomas-Tikhonenko, A.,
- 687 Ahmad, N., and Spiegelman, V.S. (2007). Role of GLI2 transcription factor in growth and
- tumorigenicity of prostate cells. Cancer Res 67, 10642–10646.
- 689 65. Zhu, S., Xu, Y., Song, M., Chen, G., Wang, H., Zhao, Y., Wang, Z., and Li, F. (2016).
- 690 PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA
- 691 interference screening. Mol Med Rep 14, 3357–3361.
- 692 66. Magani, F., Peacock, S.O., Rice, M.A., Martinez, M.J., Greene, A.M., Magani, P.S., Lyles,
- 693 R., Weitz, J.R., and Burnstein, K.L. (2017). Targeting AR Variant-Coactivator Interactions to
- Exploit Prostate Cancer Vulnerabilities. Mol Cancer Res 15, 1469–1480.
- 695 67. Zhao, L.Y., Niu, Y., Santiago, A., Liu, J., Albert, S.H., Robertson, K.D., and Liao, D. (2006).
- An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. CancerRes 66, 9445–9452.
- 698 68. Arora, A., Abdel-Fatah, T.M.A., Agarwal, D., Doherty, R., Croteau, D.L., Moseley, P.M.,
- Hameed, K., Green, A., Aleskandarany, M.A., Rakha, E.A., et al. (2016). Clinicopathological and
- 700 prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis 37,
- 701 63–71.

- 69. Chen, E., Ahn, J.S., Sykes, D.B., Breyfogle, L.J., Godfrey, A.L., Nangalia, J., Ko, A.,
- 703 DeAngelo, D.J., Green, A.R., and Mullally, A. (2015). RECQL5 Suppresses Oncogenic JAK2-
- Induced Replication Stress and Genomic Instability. Cell Rep *13*, 2345–2352.
- 705 70. Patterson, K., Arya, L., Bottomley, S., Morgan, S., Cox, A., Catto, J., and Bryant, H.E.
- 706 (2016). Altered RECQL5 expression in urothelial bladder carcinoma increases cellular
- proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. Oncotarget
  7, 76140–76150.
- 709 71. Höflmayer, D., Steinhoff, A., Hube-Magg, C., Kluth, M., Simon, R., Burandt, E., Tsourlakis,
- 710 M.C., Minner, S., Sauter, G., Büscheck, F., et al. (2020). Expression of CCCTC-binding factor
- 711 (CTCF) is linked to poor prognosis in prostate cancer. Molecular Oncology 14, 129–138.
- 712 72. Hu, X.Y., Xu, Y.M., Fu, Q., Yu, J.J., and Huang, J. (2009). Nedd4L expression is
- downregulated in prostate cancer compared to benign prostatic hyperplasia. Eur J Surg Oncol
  35, 527–531.
- 715 73. UK Biobank.
- 716 74. Elsworth, B.L. (2017). MRC IEU UK Biobank GWAS pipeline version 1.
- 717 75. Elsworth, B., Lyon, M., Alexander, T., Liu, Y., Matthews, P., Hallett, J., Bates, P., Palmer, T.,
- 718 Haberland, V., Smith, G.D., et al. (2020). The MRC IEU OpenGWAS data infrastructure
- 719 (Genetics).
- 720 76. Kichaev, G., Bhatia, G., Loh, P.-R., Gazal, S., Burch, K., Freund, M.K., Schoech, A.,
- 721 Pasaniuc, B., and Price, A.L. (2019). Leveraging Polygenic Functional Enrichment to Improve
- GWAS Power. Am J Hum Genet 104, 65–75.

- 723 77. Lotta, L.A., Wittemans, L.B.L., Zuber, V., Stewart, I.D., Sharp, S.J., Luan, J., Day, F.R., Li,
- 724 C., Bowker, N., Cai, L., et al. (2018). Association of Genetic Variants Related to Gluteofemoral
- vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular
- 726 Risk Factors. JAMA 320, 2553–2563.
- 727 78. Wang, J., Song, C., Tang, H., Zhang, C., Tang, J., Li, X., Chen, B., and Xie, X. (2017). miR629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of
  729 triple-negative breast cancer. Breast Cancer Res *19*, 72.
- 730 79. Labbé, C., Goyette, P., Lefebvre, C., Stevens, C., Green, T., Tello-Ruiz, M.K., Cao, Z.,
- Landry, A.L., Stempak, J., Annese, V., et al. (2008). MAST3: a novel IBD risk factor that
- modulates TLR4 signaling. Genes Immun 9, 602–612.
- 80. Burns, J.A., Weiner, A.B., Catalona, W.J., Li, E.V., Schaeffer, E.M., Hanauer, S.B., Strong,
- S., Burns, J., Hussain, M.H.A., and Kundu, S.D. (2019). Inflammatory Bowel Disease and the
- Risk of Prostate Cancer. Eur Urol 75, 846–852.
- 736 81. Meyers, T.J., Weiner, A.B., Graff, R.E., Desai, A.S., Cooley, L.F., Catalona, W.J., Hanauer,
- 737 S.B., Wu, J.D., Schaeffer, E.M., Abdulkadir, S.A., et al. (2020). Association between
- inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based
- 739 study. Int J Cancer *147*, 2735–2742.
- 82. Qiao, X.-R., Zhang, X., Mu, L., Tian, J., and Du, Y. (2020). GRB2-associated binding protein
  2 regulates multiple pathways associated with the development of prostate cancer. Oncol Lett
  20, 99.
- 743 83. Xu, J., Isaacs, W.B., Mamawala, M., Shi, Z., Landis, P., Petkewicz, J., Wei, J., Wang, C.-H.,
- Resurreccion, W.K., Na, R., et al. (2021). Association of prostate cancer polygenic risk score
- with number and laterality of tumor cores in active surveillance patients. Prostate *81*, 703–709.

746

#### 747 Figure Titles and Legends

# 748 Figure 1. Flow chart highlighting the approach and samples used in the genome-wide

749**association analysis.** First, we undertook a discovery GWAS in men of European ancestry.750Fourteen SNPs were associated with conversion ( $P < 5 \times 10^{-8}$ ). All SNPs were evaluated for751replication in the replication cohorts alone and then in a meta-analysis combining the discovery752and replication cohorts. Four additional SNPs reached statistical significance in the combined753meta-analysis ( $P < 5 \times 10^{-8}$ ).

754

## 755 Figure 2. Results from the GWASs of conversion from AS to treatment (a) in 5,222

prostate cancer patients of European ancestry; (b) in discovery and replication cohorts. P values are for variant associations with conversion, adjusted for age and ten ancestry principal components using Cox proportional hazards models. Blue dashed line denotes the genomewide significance threshold. Orange peaks indicate genome-wide significant hits ( $P < 5 \times 10^{-8}$ ). The top variants in each chromosome are annotated with their rsID.

761

Figure 3. Association between time to conversion from AS to treatment (a) with the prostate cancer GRS; (b) with the prostate-specific antigen GRS . The fifth and sixth deciles of prostate cancer GRS are used as the reference. Bars indicate 95% confidence intervals (CI) around the hazard ratio (HR) estimates. The minimally adjusted model includes age and the first 10 genetic prinicpal components. The fully adjusted model also includes Gleason grade group (GG1, GG2, or  $\geq$  GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or  $\geq$  4).

769

770 Figure 4. Kaplan-Meier plots of active surveillance conversion-free probability for low,

intermediate, and high clinicopathological risk categories. The plots are stratified by the top

- and bottom deciles of genetic risk scores for prostate cancer (GRS<sub>PC</sub>, panel a) and for PSA
- 773 levels (GRS<sub>PSA</sub>, panel b). The curves within each risk category are compared between the top
- and bottom GRS deciles using a log-rank test (P-values given next to corresponding curves).

# Table 1. Results for 4 common and 14 variants associated with conversion from AS to treatment in a genome-wide association analysis.

					HR (95% CI), p-value								
rsid	Chr	Gen es	Risk Allele / ref allele	RA F	Discovery European			Replication meta- analysis			Combined meta-analysis		
Common													
variants rs771129 78	18	ATP8B 1 NEDD4 1ª	G/C	0.048	1.4 1	(1.23 - 1.63)	1.51 × 10 <sup>-6</sup>	2.24	(1.38 - 3.65)	1.14 × 10 <sup>-3</sup>	1. 47	(1.28 - 1.68)	$3.26 \times 10^{-8}$
rs558508 37	18	MC4R CDH20 a	A/G	0.050	1.4 2	(1.24 - 1.63)	3.43 × 10 <sup>-7</sup>	1.92	(1.09 - 3.36)	0.0232	1. 45	(1.27 - 1.65)	4.03 × 10 <sup>-8</sup>
rs178785 33	19	IL12RB 1 <sup>b</sup>	A/G	0.651	1.2 3	(1.14 - 1.32)	$4.56 \times 10^{-8}$	0.94	(0.75 - 1.18)	0.582	1. 2	(1.12 - 1.28)	4.86 × 10 <sup>-7</sup>
rs748741 16	20	RBBP8 NL GATA5 ª	T/G	0.028	2.6 7	(1.94 - 3.66)	$1.47 \times 10^{-9}$	1.23	(0.93 - 1.64)	0.146	1. 74	(1.41 - 2.15)	3.14 × 10 <sup>-7</sup>
Rare		-											
variants rs665866 4	1	PRDM1 6⁵	A/G	0.014	5.1 9	(3.33 – 8.09)	$3.55 \times 10^{-13}$	0.94	(0.67 - 1.33)	0.746	1. 79	(1.37 – 2.46)	2.58 × 10 <sup>-5</sup>
rs140461	2	LINC01	G/A	0.012	15.	(4.64 -	6.69	3.07	(1.97 -	7.84	3.	(2.47 -	5.37
0		101 GLI2ª			15	49.5)	$\times 10^{-6}$		4.79)	$\times 10^{-7}$	74	5.67)	$\times 10^{-10}$
rs116419 656	3	FAM86 DP MIR132 4ª	G/A	0.010	6.8 9	(4.03 - 11.8)	$1.95 \times 10^{-12}$	0.96	(0.47 - 2.00)	0.923	3. 45	(2.24 - 5.32)	2.06 × 10 <sup>-8</sup>
rs472124 3	7	MAD1L 1 <sup>b</sup>	A/G	0.010	5.6 5	(3.26 – 9.8)	$7 \times 10^{-10}$	0.78	(0.5 – 1.22)	0.28	1. 70	(1.2 – 2.39)	2.6 × 10 <sup>-3</sup>
rs113658 888	8	MROH 1⁵	T/C	0.011	3.8 6	(2.60 - 5.74)	$2.52 \times 10^{-11}$	1.22	(0.84 <sup>´</sup> - 1.78)	0.305	2. 11	(1.6 - 2.77)	$9.04 \times 10^{-8}$
rs115861 550	9	VAV2 <sup>b</sup>	T/C	0.010	7.5 1	(4.48 <sup>´</sup> - 12.6)	$2.03 \times 10^{-14}$	1.01	(0.69 <sup>´</sup> - 1.48)	0.943	2. 05	(1.51 <sup>°</sup> - 2.79)	$4.26 \times 10^{-6}$
rs375082 7	10	EBF3 <sup>b</sup>	A/G	0.011	2.4	(1.79 <sup>°</sup> - 3.21)	$5.05 \times 10^{-9}$	1.78	(1.04 <sup>-</sup> 3.03)	0.035	2. 24	(1.73 <sup>°</sup> - 2.89)	8.29 × 10 <sup>-10</sup>
rs285149 69	11	TSPAN 4 <sup>b</sup>	C/T	0.011	14. 16	(5.78 - 34.7)	6.69 × 10 <sup>-9</sup>	1.49	(0.92 - 2.39)	0.103	2. 44	(1.6 - 3.72)	3.16 × 10 <sup>-5</sup>
rs563064	13	F10 <sup>c</sup>	A/G	0.010	34. 03	(10.4 - 111)	$4.59 \times 10^{-9}$	2.2	(1.45 - 3.34)	1.96 × 10 <sup>-4</sup>	2. 98	(2.01 - 4.41)	4.89 × 10 <sup>-8</sup>
rs820198	17	RECQL 5⁵	T/C	0.010	14. 26	(6.56 – 31.0)	$2.03 \times 10^{-11}$	1.2	(0.67 - 2.17)	0.537	2. 97	(1.86 - 4.75)	5.50 × 10 <sup>-6</sup>
rs124526 25	17	RFNG <sup>d</sup>	A/G	0.011	3.8 4	(2.65 - 5.57)	$1.20 \times 10^{-12}$	1.03	(0.68 <sup>°</sup> - 1.56)	0.878	2. 14	(1.62 - 2.82)	6.84 × 10 <sup>-8</sup>
rs590277 29	19	HCN2 <sup>b</sup>	A/G	0.014	2.0 6	(1.58 - 2.68)	$7.24 \times 10^{-8}$	1.47	(0.92 <sup>-</sup> - 2.34)	0.109	1. 90	(1.51 - 2.39)	4.25 × 10 <sup>-8</sup>
rs116837 676	19	MYAD M⁵	A/G	0.011	5.4 2	(3.00 <sup>°</sup> - 9.77)	$2.01 \times 10^{-8}$	1.72	(1.17 <sup>´</sup> - 2.53)	5.66 × 10 <sup>-3</sup>	2. 42	(1.76 <sup>°</sup> - 3.34)	7.34 × 10 <sup>-8</sup>
rs560649 12	Х	POF1B MIR132 1ª	T/G	0.010	24. 7	(8.95 <sup>°</sup> - 68.3)	6.13 × 10 <sup>-10</sup>	1.07	(0.85 <sup>°</sup> - 1.36)	0.55	1. 26	(1 – 1.59)	0.0475

Chr, chromosome; Ref, reference; RAF = Risk allele frequency; HR, hazard ratio; CI, Confidence Interval. SNPs included here are those with association  $P < 5 \times 10^{-8}$  either in European discovery GWAS or combined meta-analysis of all samples.

In the Genes column

<sup>a</sup> Intergenic (genes are two flanking)

<sup>b</sup> Intronic

<sup>c</sup> Upstream

<sup>d</sup> UTR3



(a)









#### Figure 4



